Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference
NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will participate in the investor-focused Cantor Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference taking place in Miami December 7-8, 2022. Akari President and CEO Rachelle Jacques will take part in an ophthalmology panel on December 8 at 1:45 pm ET, Vision for the Future: Dry AMD, Other Greenfield Opportunities, and Late-Stage Stories to Shake Things Up. The Akari management team also will attend 1:1 investor meetings at the conference to discuss progress in the promising pre-clinical program that is investigating long-acting PAS-nomacopan in geographic atrophy (GA).
Related news for (AKTX)
- MoBot’s Stock Market Highlights – 09/24/25 02:00 PM
- Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
- Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA
- Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification